Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ipratropium bromide 20micrograms/dose inhaler CFC free
0301020I0AAANAN
|
Ipratropium bromide (Bronchodilators) | Ipratropium bromide | Respiratory System | 38,237 |
|
Ipratropium bromide 21micrograms/dose nasal spray
1202020I0AAABAB
|
Ipratropium bromide (Nasal) | Ipratropium bromide | Ear, Nose and Oropharynx | 25,191 |
|
Ipratropium bromide 500micrograms/2ml neb liq ud vials
0301020I0AAACAC
|
Ipratropium bromide (Bronchodilators) | Ipratropium bromide | Respiratory System | 13,408 |
|
Atrovent 20micrograms/dose inhaler CFC free
0301020I0BBAJAN
|
Atrovent | Ipratropium bromide | Respiratory System | 10,281 |
|
Ipratropium bromide 250micrograms/1ml neb liq ud vials
0301020I0AAAFAF
|
Ipratropium bromide (Bronchodilators) | Ipratropium bromide | Respiratory System | 5,427 |
|
Rinaspray 21micrograms/dose nasal spray
1202020I0BBABAB
|
Rinatec | Ipratropium bromide | Ear, Nose and Oropharynx | 5,122 |
|
Atrovent 500micrograms/2ml nebuliser liquid UDVs
0301020I0BBACAC
|
Atrovent | Ipratropium bromide | Respiratory System | 1,288 |
|
Atrovent 250micrograms/1ml nebuliser liquid UDVs
0301020I0BBAFAF
|
Atrovent | Ipratropium bromide | Respiratory System | 992 |
|
Ipratropium 500micrograms/2ml neb liq Steri-Neb ud vials
0301020I0BEABAC
|
Ipratropium Steri-Neb | Ipratropium bromide | Respiratory System | 599 |
|
Ipratropium 250micrograms/1ml neb liq Steri-Neb ud vials
0301020I0BEAAAF
|
Ipratropium Steri-Neb | Ipratropium bromide | Respiratory System | 497 |
|
Inhalvent 20micrograms/dose inhaler
0301020I0BIAAAN
|
Inhalvent | Ipratropium bromide | Respiratory System | 53 |
|
Ipravent 20micrograms/dose inhaler CFC free
0301020I0BJAAAN
|
Ipravent | Ipratropium bromide | Respiratory System | 21 |
|
Ipratropium 250micrograms/1ml neb liq ud Steripoule vials
0301020I0BHAAAF
|
Ipratropium Steripoule | Ipratropium bromide | Respiratory System | 5 |
|
Respontin 500micrograms/2ml Nebules
0301020I0BGABAC
|
Respontin | Ipratropium bromide | Respiratory System | 2 |
|
Respontin 250micrograms/1ml Nebules
0301020I0BGAAAF
|
Respontin | Ipratropium bromide | Respiratory System | 1 |
|
Atrovent 20micrograms/dose Autohaler
0301020I0BBAGAG
|
Atrovent | Ipratropium bromide | Respiratory System | No data available |
|
Atrovent 20micrograms/dose inhaler
0301020I0BBAAAA
|
Atrovent | Ipratropium bromide | Respiratory System | No data available |
|
Atrovent 40microgram Aerocaps
0301020I0BBAIAI
|
Atrovent | Ipratropium bromide | Respiratory System | No data available |
|
Atrovent 40microgram Aerocaps with Aerohaler
0301020I0BBAHAH
|
Atrovent | Ipratropium bromide | Respiratory System | No data available |
|
Atrovent Forte 40micrograms/dose inhaler
0301020I0BBADAD
|
Atrovent | Ipratropium bromide | Respiratory System | No data available |
|
Ipratropium 500micrograms/2ml neb liq ud Steripoule vials
0301020I0BHABAC
|
Ipratropium Steripoule | Ipratropium bromide | Respiratory System | No data available |
|
Ipratropium bromide 20micrograms/dose BA inhaler
0301020I0AAAGAG
|
Ipratropium bromide (Bronchodilators) | Ipratropium bromide | Respiratory System | No data available |
|
Ipratropium bromide 20micrograms/dose inhaler
0301020I0AAAAAA
|
Ipratropium bromide (Bronchodilators) | Ipratropium bromide | Respiratory System | No data available |
|
Ipratropium bromide 40microgram inhalation pdr caps with dev
0301020I0AAAHAH
|
Ipratropium bromide (Bronchodilators) | Ipratropium bromide | Respiratory System | No data available |
|
Ipratropium bromide 40microgram inhalation powder capsules
0301020I0AAAIAI
|
Ipratropium bromide (Bronchodilators) | Ipratropium bromide | Respiratory System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.